ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
about
The multidrug transporter ABCG2: still more questions than answersGenetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic reviewPediatric Statin Administration: Navigating a Frontier with Limited DataThe Effect of Albumin on MRP2 and BCRP in the Vesicular Transport AssayMembrane transporters in drug developmentRacial Differences in the Cholesterol-Lowering Effect of Statin.ABC Transport Proteins in Cardiovascular Disease-A Brief Summary.Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.The challenge of exploiting ABCG2 in the clinic.Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.The emerging role of electronic medical records in pharmacogenomics.Dyslipidemia in special ethnic populationsIndividualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsA pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population.Improving cancer chemotherapy with modulators of ABC drug transporters.Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.What do drug transporters really do?Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein TransporterCurrent Perspectives on rosuvastatin.Drug-drug interaction studies: regulatory guidance and an industry perspectiveMolecular mechanisms of statin intoleranceGenetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.A perspective on efflux transport proteins in the liverPilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain BarrierHepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytesHepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.
P2860
Q26747187-F1AB1D0D-6CCF-483A-9C8A-0ECEE762520AQ26823434-A6165525-83F9-4686-9506-9C266BA5A388Q28068014-937BAF5F-8DB3-4547-A956-E0B3674BDA2CQ28554497-DE2E6E6E-5601-45A8-BFEB-1CF4E3F74AD5Q29616802-1912B7F0-D6D1-40BD-A01E-65EFFA764854Q30244632-7A489D4E-CC69-41C2-B246-77150999ED8FQ30313271-D4FCF261-25B1-4F44-A488-81FD49F47660Q30582571-9BCBCD1E-4086-4126-9236-A09777521D47Q30616911-7FEC779F-3C2F-4F1C-9583-95C16CB3ED9EQ33581531-192584AA-8F56-481F-9B99-8B4AF417D956Q33714593-F50257D8-BE5E-4743-A3CE-30E9EB437C4FQ34176588-3CF15D1D-6034-4238-B479-B131A75F62B8Q34571070-CD037CA2-ABDD-4A6B-9837-50743C529BCBQ34613443-5ED6C392-F1F2-4A02-B70F-5E093424B337Q34680467-78A6ABC4-8F01-4F00-9B98-224EB1780230Q34871636-8DB0FAA7-2AD9-45AB-9DBA-1F53C57D7DAEQ34968909-BE939FBD-CDBF-43F7-AE67-5C9D8BDD6D5EQ35183649-8BEC350F-CE12-4DD3-88D6-620A988FE8EEQ35478918-A4C09866-C3D4-4B15-B433-698DF7ADB28CQ35573543-234BB011-4E4B-4256-B3AC-5D4F0370D837Q35915932-C3AE4C89-7B0B-48E2-AB08-040A424F1F80Q35917726-D3CEB19A-3FED-40A3-8226-26633AF44B0AQ36050960-FCD915D3-D81B-4382-8DE0-5E4B0CAB3610Q36108251-9DD07D26-3FC9-49C3-BF69-80EE02F90219Q36110576-E4428771-8602-438C-BC04-2DDCDDC30F9BQ36571217-C2EEAD01-FEEB-4157-A138-1C078B86ABD8Q36620076-EF7176AB-FA15-4D80-B0D1-3E5E9010E038Q36733503-A10D6BC7-81DE-4E67-AC4D-61154430C120Q36796490-57B7D628-C6F2-4782-BE95-07D68B7D6694Q36951933-5C8A4869-F1F9-4937-98EF-CC351BFAF14BQ36958324-7CA5E9D7-41E8-4CA7-BA99-FD0D5EDDDBFFQ36998199-0A6FBF1E-9434-4263-9F83-50DFFD67B2A1Q37017426-50EBA3CA-E703-47D3-A0DF-0E3ED922F920Q37050337-EA88CA89-316B-4A2D-B711-62543637DFDEQ37164563-F5468CEF-2D85-436F-81DD-AC0297E267ADQ37331801-DEC550AB-5A27-4DAC-AD93-5D204724F562Q37331821-ED01A51F-EF17-498C-A334-924912772B54Q37392745-F7F30D1D-71F6-4550-BCAB-66FBA8DF54F4Q37394474-44EDC13E-E8E7-4951-A0A2-897B4912F5C9Q37504548-714F19D8-3B96-4A14-A1C7-F15A667FCEC0
P2860
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@en
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@nl
type
label
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@en
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@nl
prefLabel
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@en
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@nl
P2093
P2860
P50
P356
P1476
ABCG2 polymorphism markedly af ...... atorvastatin and rosuvastatin.
@en
P2093
J E Keskitalo
K J Kurkinen
P2860
P304
P356
10.1038/CLPT.2009.79
P407
P577
2009-05-27T00:00:00Z